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Introduction
The circadian rhythm is a biochemical and biophysical process that has an approximately 24-hour cycle and is driven by the endogenous clock system (1) . The hierarchically organized network of the circadian clocks regulate various physiological processes in the human body, including blood pressure, hormone secretion, sleep and immune activity (2) . Deregulation of circadian rhythms can result in increased risk of cardiovascular diseases, immune system diseases and cancer (3, 4) .
The Bmal1 gene, encodes the Bmal1 protein, is a core component of the circadian clock in mammals (5) . Bmal1 belongs to the bHLH-PAS structural domain transcription factor family, which controls the circadian genes Per, Cry and Rev-Erbα and maintains the normal circadian rhythm (6, 7) . In addition to its function in controlling biological rhythm, Bmal1 is closely related to aging, angiocardiopathy, immune disorders and cancers (8) (9) (10) (11) (12) . Recent evidence suggests that Bmal1 is correlated with proliferation and the cell cycle, indicating that Bmal1 may play an important role in tumorigenesis (11, (13) (14) (15) . For instance, Bmal1 has been shown to affect the cell cycle and cell proliferation by regulating the p53/p21 signaling pathway (14, 15) . Epigenetic inactivation of Bmal1 is associated with the development of B-cell lymphoma and certain types of leukemia, whereas the reintroduction of Bmal1 inhibits of cancer cell growth in vitro and in vivo (11) .
Colorectal cancer (CRC) is the third most common cancer diagnosed in both men and women, and is the third leading cause of cancer-related deaths in the United States according to the American Cancer Societyin 2013. Over 1 million new cases of CRC are clinically diagnosed each year, and more than 500,000 patients die from CRC annually (16) . More than 20% of CRC cases are diagnosed at a late stage, and this percentage is higher in developing countries (17) . Thus, many patients experience recurrence after colorectal resection.
Oxaliplatin, a platinum-based, antineoplastic agent, is used in combination with 5-fluorouracil as the standard first-line chemotherapy for CRC (18, 19) . The timing of oxaliplatin administration affects its toxicity and efficacy. For example, when compared with constant-rate administration, the administration of oxaliplatin, 5-fluorouracil and leucovorin using a programmable infusion pump confers a 5-fold improvement in patient tolerability and a nearly 2-fold increase in antitumor activity in patients with advanced CRC (20) . This could be due in part to the fact that the circadian system controls drug metabolism and the expression of drug targets as well as cell cycle progression, DNA repair and apoptosis (21, 22) .
Disturbance of the circadian rhythms results in accelerated tumor growth in mice and poor survival in CRC patients undergoing oxaliplatin-based chemotherapy (23) (24) (25) .
Bmal1-deficient fibroblasts show reduced sensitivity to DNA-damaging anticancer drugs, such as etoposide and daunorubicin (8) . However, the clinical significance of Bmal1 in CRC remains largely unknown, and the relationship between Bmal1 and oxaliplatin is unclear. Furthermore, the mechanism by which Bmal1 affects the sensitivity of cancer cells to DNA-damaging anticancer drugs requires further study.
In this study, we provide evidence suggesting that Bmal1 might inhibit the proliferation of CRC cells and that Bmal1 upregulation could enhance the sensitivity of CRC cells to oxaliplatin in vitro and in vivo. Furthermore, we show that Bmal1 protein expression correlates with the outcome of oxaliplatin-based first-line chemotherapy in advanced CRC patients. Moreover, the effect of Bmal1 appears to be mechanistically associated with its ability to regulate G2/M phase arrest by activating the ataxia telangiectasia mutated (ATM) signaling pathway.
Research. 
Xenografted tumor model
Male BALB/c nude mice (4-5 weeks of age, 18-20 g) were purchased from the Guangdong Province Laboratory Animal Center (Guangzhou, China). All mice were synchronized with a 12-h light/dark cycle in an autonomous chronobiological animal facility (Sujing, Suzhou, China), with the lights on from 6 am (Zeitgeber time 0) to 6 pm (Zeitgeber time 12) for 3 weeks, after which they were randomly assigned to groups. All experimental procedures were approved by the Institutional Animal Care and Use Committee of Sun Yat-sen University.
Two in vivo experiments were designed. In experiment 1, the mice were randomly divided into the HCT116_EV, HCT116_Bmal1, HCT116_EV+L-OHP and HCT116_Bmal1+L-OHP groups (n=6 per group), and equal amounts of HCT116_Bmal1 or control cells (2×10 6 ) were injected subcutaneously into the flank of each mouse. In experiment 2, the mice were also
Vectors and siRNA transfection
A Bmal1 expression construct was generated by sub-cloning PCR-amplified full-length human Bmal1 cDNA into the pMSCV plasmid. Recombinant retroviral vectors were generated and viral infection was performed as previously described (26) . Stable cell lines expressing Bmal1 were selected over 10 days with 2 μg/mL puromycin. To verify the stable high expression of Bmal1 in these cell lines, western blotting was performed after 30 generations of cell culture (Suppl. Fig. 1 ). For Bmal1 knockdown, we used the following siRNA sequences: GAACTTCTAGGCACATCGT (siRNA#1) and GGGAAGCTCACAGTCAGAT (siRNA#2) (synthesized by Ribobio, Guangzhou, China).
Transfection of the Bmal1 siRNA was carried out using Lipofectamine 2000 (Invitrogen,
Grand Island, NY, USA) according to the manufacturer's instructions and the cells were harvested 72h post-transfection for western blotting to verify and quantify the knockdown of Bmal1.
Immunohistochemistry (IHC)
IHC and the scoring of the Bmal1 staining intensity were performed as previously described (27) (28) (29) . 0, >10% to ≤ 25% = 1, >25% to ≤ 50% = 2, >50% to ≤ 75% = 3 and >75% = 4. The staining intensity was scored as follows: negative = 0, weak = 1, moderate = 2 and strong = 3. A final score was then calculated by multiplying these two scores. If the final score was ≤4, the tumor was considered to have low Bmal1 expression; whereas scores >4 indicated high Bmal1 expression.
Western blotting
Western blotting was performed according to standard methods, as described previously (30), using anti-Bmal1 (Lifespan, Seattle WA, USA), anti-ATM, anti-CHK2, anti-pCHK2
Thr68 ,
anti-p53, anti-MDM2 and anti-Wee1 antibodies (Cell Signaling, Danvers, MA, USA). An anti-α-tubulin mouse monoclonal antibody (Sigma, Saint Louis, MO, USA) was used as a loading control.
MTT assay
Cells were seeded in 96-well plates (NEST, Shanghai, China) at an initial density of 2×10 The absorbance was measured at 570 nm, and 630 nm was used as the reference wavelength.
All experiments were conducted in triplicate.
Colony formation assays
Cells were plated in 6-well plates (NEST, Shanghai, China) at 5×10 2 cells/well and cultured for 10 days. The colonies were fixed with 10% formaldehyde for 5 min and then stained with 1% crystal violet for 30 sec.
Flow cytometry
Cells were harvested and washed with cold PBS, and the cell cycle distribution and apoptosis
Research. For apoptosis analysis, after washing with cold PBS, the cells were stained with annexinV-FITC and PI (Keygen, Nanjing, China), according to the manufacturer's instructions.
Statistical analysis
All statistical analyses were performed using the SPSS version 16.0 statistical software packages. Statistically significant differences between groups were determinied using a 2-tailed, paired Student's t-test. Survival curves were plotted using the Kaplan-Meier method, and the different groups were compared using the log-rank test. A p-value of < 0.05 was considered to be statistically significant in all cases.
Results

Bmal1 inhibits CRC cell proliferation
To evaluate the role of Bmal1 in CRC cell proliferation, three CRC cell lines were chosen:
HCT116 and THC8307, with low Bmal1 expression; and HT29, with high Bmal1 expression (Suppl. Fig. 2) . We established the three cells stably expressing ectopic Bmal1, with Bmal1 expression more than twice as high as compared to control cell lines (Fig. 1A and Suppl. Fig.   3A ). A siRNA specific for Bmal1 was transfected to knock down the expression of Bmal1 in HCT116, THC8307 and HT29 cells with more than 70% inhibition of Bmal1 expression (Fig.   1B and Suppl. Fig. 3B ). A significant decrease in cell proliferation was observed in Bmal1-overexpressing cells compared with the vector control cells (Fig. 1C) . These results were confirmed by colony formation assays, which showed a more than 45% decrease in the number of cell colonies in the Bmal1-overexpressing cells compared with control cells (Fig.   1D ).
To further explore the significance of the proliferative function of Bmal1 in CRC cells, HCT116, THC8307 and HT29 cells were transiently transfected with specific siRNAs against Bmal1. Knockdown of Bmal1 signficantly increased cell proliferation compared with control siRNA-transfected cells (Fig. 1C) .
Overexpression of Bmal1 increases oxaliplatin sensitivity in vitro
To explore the effect of Bmal1 on the activity of the anticancer agent oxaliplatin in CRC cells, MTT and colony formation assays were performed in HCT116, THC8307 and HT29 cells. Cells overexpressing Bmal1 were more sensitive to oxaliplatin than cells expressing the control vector (Fig. 2A) were more resistant to oxaliplatin (Fig. 2B) μM, respectively, for the THC8307 cells; and 28.61±2.12, 34.44±3.14 and 14.82±1.52μM, respectively, for the HT29 cells. These results were confirmed by colony formation assays using Bmal1-overexpressing cells (Fig. 2C and 2D) .
Overexpression of Bmal1 increases oxaliplatin sensitivity in vivo
To further investigate whether Bmal1 overexpression affects oxaliplatin sensitivity in vivo, unsynchronized, log-phase Bmal1-overexpressing or control HCT116 cells were injected subcutaneously into Balb/c nude mice. To exclude differences in the cell proliferation rate between these cell lines, two experiments were designed: in experiment I, equal amounts of Bmal1-overexpressing or control cells (2×10 6 ) were injected subcutaneously; in experiment II, different amounts of Bmal1-overexpressing (3×10 6 ) or control (2×10 6 ) cells were injected.
The tumors derived from the HCT116 cells overexpressing Bmal1 were significantly more sensitivite to oxaliplatin compared with the HCT116 vector control tumors (p<0.001). In experiment I, the oxaliplatin-mediated growth inhibition rates of the Bmal1-overexpressing tumors and the control tumors were 81.5% and 39.6%, respectively (Fig. 3A) ; in experiment II, the oxaliplatin-mediated growth inhibition rates of the Bmal1-overexpressing tumors and the control tumors were 73.6% and 38.2%, respectively (Fig. 3B ).
Bmal1 protein expression correlates with the outcome of oxaliplatin-based first line chemotherapy in advanced CRC patients
To further confirm the effect of Bmal1 expression on oxaliplatin activity, IHC staining for Bmal1 expression was also dramatically longer than those with low Bmal1 expression (median PFS: 11 months vs 5 months, respectively; p=0.015) (Fig. 3C) . 
Bmal1 enhances oxaliplatin induced apoptosis in CRC cells
We further examined whether Bmal1 increase the sensitivity of CRC cells to oxaliplatin by enhancing the rate of apoptosis. An annexinV-PI assay was used to detect cellular apoptosis. Bmal1-overexpressing cells displayed increased cellular apoptosis and necrosis in response to oxaliplatin treatment for 48 h (Suppl. Fig. 4) . However, these phenomena were observed at only high oxaliplatin concentrations. Furthermore, the difference in the apoptosis rate between the Bmal1-overexpressing cells and the control cells was not large enough to explain the significant changes in the response to oxaliplatin treatment that were observed in vitro and in vivo. Thus, other mechanisms might be involved in this process.
Bmal1 regulates oxaliplatin-mediated G2/M phase arrest in CRC cells
To assess cell cycle distribution, flow cytometry was performed on Bmal1-overexpressing and control cells after oxaliplatin treatment. The cells were incubated with oxaliplatin for 6 h and then in drug-free medium for the next 42 h, and the cell cycle distribution was assessed.
The Bmal1-overexpressing cells demonstrated a dramatically higher number of cells in G2/M phase compared with the control cells (Fig. 4A-C) , suggesting that Bmal1 regulates G2/M phase arrest in response to oxaliplatin.
Bmal1 is involved in the G2/M checkpoint
Because Bmal1 regulates G2/M phase arrest in response to oxaliplatin, we hypothesized that Bmal1 is involved in the G2/M checkpoint. The ATM pathway activates DNA damage checkpoint proteins which results in G2/M phase arrest. Therefore, we assessed the expression of ATM, pCHK2
Thr68 , CHK2, p53, MDM2 and Wee1 by western blotting in HCT116 and THC8307 cell lines. As expected, compared with the control cells, the expression levels of ATM, pCHK2 Thr68 , p53 and Wee1 were significantly upregulated and MDM2 was downregulated in the Bmal1-overexpressing cells after oxaliplatin treatment (Fig.   5 ). These results suggest that the ATM pathway plays an important role in the ability of Bmal1 to increase sensitivity to oxaliplatin.
Discussion
In the present study, we found that Bmal1 inhibits the proliferation of CRC cells, and that Bmal1 overexpression increases the sensitivity of CRC to the anticancer drug oxaliplatin in vitro and in vivo. Furthermore, we demonstrated that Bmal1 protein expression correlates with the outcome of oxaliplatin-based first-line chemotherapy in advanced CRC patients, as patients with high tumor Bmal1 expression more frequently benefited from oxaliplatin-based chemotherapy when compared with patients with low Bmal1 expression. Additionally, we determined that the mechanism underlying the effects of Bmal1 is associated with the ability of Bmal1 to regulate G2/M phase arrest by activating the ATM signaling pathway. To the best of our knowledge, this study is the first demonstrating that Bmal1 is involved in the effect of oxaliplatin on CRC The current trend in chemotherapy is personalized medicine, and identifying novel biomarkers and therapeutic targets is a major focus of ongoing research. Herein, we systematically explored the effect of Bmal1 on oxaliplatin sensitivity in CRC in cells, mice and clinical samples. This study is the first to explore the role of Bmal1 in chemotherapy in conjunction with clinical features and prognostic data. We found that patients with high tumor Bmal1 expression levels had better outcomes compared with those with low Bmal1 expression (median OS: 27 months vs. 19 months, respectively). Impressively, the PFS of patients with high Bmal1 expression was also dramatically longer than that of patients with low Bmal1 expression (median PFS: 11 months vs. 5 months, respectively). Thus, our study provides strong evidence that Bmal1 is a potential prognostic biomarker and therapeutic target for treating human CRC. fibroblasts have reduced sensitivity to the DNA damage-inducing anticancer drugs, etoposide and daunorubicin (8) . Our previous study also demonstrated that Bmal1 plays a role involved in the effect of cisplatin in mice (33) . In the present study, we found that Bmal1 overexpression induces G2/M phase arrest in HCT116 and THC8307 cell lines after oxaliplatin treatment, indicating that the DNA damage-repair signaling pathway is involved in this process. Previous reports have suggested that Bmal1 affects the efficacy of DNA damage-inducing anticancer drugs and that this function is related to the circadian gating control of the cell cycle and cell proliferation (21, 34) . The Bmal1/Clock heterodimer negatively controls the cell cycle and cell proliferation by repressing c-myc and p21 and activating p53 and Wee1, which results in DNA damage-induced cell cycle arrest or apoptosis (21, 35, 36) . DNA double-strand breaks recruit and activate the ATM (ataxia telangiectasia mutated) protein, which then activates DNA damage checkpoint proteins, such as CHK2 and p53, leading to cell cycle arrest or apoptosis (37) . Some clock genes that control the ATM pathway have been reported, including per1, per2 and timeless (38) (39) (40) (41) . We also demonstrated that the ATM signaling pathway plays an important role in G2/M phase arrest in CRC cells.
Oxaliplatin, a third-generation platinum analogue, functions by forming both inter-and intra-strand cross-links in DNA, thus preventing DNA replication and transcription and resulting in cell death (42) . Although our study was a retrospective study in which the sampling time could not be controlled, the chemotherapy timing followed the regimens described in the Materials and Methods section, making our data comparable. Thus, we found that Bmal1 overexpression increases the sensitivity of CRC to oxaliplatin, which is consistent with previous observations indicating that circadian timing can significantly modify drug efficiency and tolerability in tumor models and cancer patients (22, 43) . In future studies, shRNA should be used to test the effects of Bmal1 knockdown on tumor growth and drug sensitivity in animals because such experiments will further demonstrate the role of Bmal1 in tissues is lower than that in matched healthy mucosa (44) . Additionally the expression of Bmal1 and Per1 also correlates with liver metastasis and CRC outcomes (45) . Our data support the hypothesis that Bmal1 has the potential to be a novel prognostic biomarker and a new therapeutic target in CRC. Future studies should focus on collecting blood samples at a specific time of the day to avoid complications due to the influence of circadian rhythms.
Our experiments suggest that Bmal1 inhibits the proliferation of CRC cells in vitro and in vivo. Our findings are consistent with those of multiple studies demonstrating the role of Bmal1 in the suppression of cell proliferation, indicating that Bmal1 is a potential tumor suppressor gene (13) (14) (15) . In contrast to our findings, another recent study reported that Bmal1 promotes proliferation in malignant pleural mesothelioma (46) . Based on this difference, we suspect that Bmal1 might play different roles in different tumor types, which further highlights the complicated mechanisms involved in tumorigenesis.
In conclusion, our results suggest that Bmal1 plays an important role in determining the sensitivity of human CRC to oxaliplatin. A complete understanding of the precise role of Bmal1 in advanced CRC may allow for the use of Bmal1 as a prognostic biomarker for patient response to oxaliplatin-based chemotherapy and aid in the development of novel therapeutic strategies.
